2025

• Interferon-alpha Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial — Yong MK, et al. Clin Infect Dis. 2025.
• Elucidating novel immune profiles for predicting infection in high-risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia — Williams LJ, et al. Clin Transl Immunology. 2025
• Emerging concepts of CMV in transplantation — Westall GP, et al. Intern Med J. 2025
• Glucocorticoid Dosing and Implications for Vaccination: Evolution of Global Definitions — Wang X, et al. Clin Infect Dis. 2025
• Antifungal stewardship in Australian hospitals: defining the scope and future targets — Urbancic KF, et al. Intern Med J. 2025
• Epidemiology, Significance and Clinical Outcomes of Bloodstream Infections Caused by Non-Candida and Non-Cryptococcus Yeasts — Stewart AG, et al. Mycoses. 2025
• Population-based longitudinal study over two decades of Candida and Candida-like species bloodstream infection reveals gender and species differences in mortality, recurrence and resistance — Stewart AG, et al. J Infect. 2025
• Clinical Characteristics and Outcomes in Patients With Cryptococcaemia From a Large Population-Based Cohort — Stewart AG, et al. Mycoses. 2025
• Antibiotic Exposure and Risk of Allograft Rejection and Survival After Liver Transplant: An Observational Cohort Study From a Tertiary Referral Centre — Smibert OC, et al. Transpl Infect Dis. 2025
• Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU study — Roberts JA, et al. Intensive Care Med. 2025
• The bottom line of CAR-T fungal risk: low incidence, high stakes and the need for individualised antifungal prophylaxis — Reynolds GK, Slavin MA. Transplant Cell Ther. 2025
• Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study — Puerta-Alcalde P, et al. Int J Infect Dis. 2025
• Prolonged versus single dose in penicillin oral challenge testing: protocols for a pilot and definitive randomised controlled trial (PROSPECTOR studies) — Ng I, et al. BMJ Open. 2025
• Current Practice Patterns and Educational Needs of Immunocompromised Infectious Diseases Physicians in Australia and New Zealand — Marinelli T, Teh B, Giannella M, Ison MG, Roberts MB, Bupha-Intr O, Slavin M; Australasian Society for Infectious Diseases Immunocompromised Host Special Interest Group. Transpl Infect Dis. 2025
• Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study — Maertens JA, et al. Lancet Infect Dis. 2025
• Infections during novel myeloma therapies — Liu AJ, et al. Leuk Lymphoma. 2025
• From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts — Kinsella P, et al. Expert Rev Anti Infect Ther. 2025
• American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients — Khawaja F, et al. Transplant Cell Ther. 2025
• Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals — Khanina A, et al. J Antimicrob Chemother. 2025